<DOC>
	<DOCNO>NCT02336984</DOCNO>
	<brief_summary>The purpose study treat patient Ductal carcinoma situ ( DCIS ) combine treatment DC1 vaccine Trastuzumab . In study investigator assess safety immunogenicity combination therapy . The target population woman 18 year age diagnosis DCIS express HER-2 3 positive . Participants receive 6 vaccine along 2 dos trastuzumab . This study begin Abramson Cancer Center University Pennsylvania continue H. Lee Moffitt Cancer Center Research Institute .</brief_summary>
	<brief_title>A Phase I/II Trial HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab Patients With DCIS</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women &gt; = 18 year . Ductal carcinoma situ ( DCIS ) express HER2 3+ 10 % DCIS definitive surgery diagnose core biopsy NL surgical biopsy positive margin . Patients ER+ take antiestrogen therapy treatment DCIS vaccination . Women childbearing age negative pregnancy test document prior enrollment . Eastern Cooperative Oncology Group ( ECOG ) Performance Status Score 0 1 . Women childbearing potential must agree use medically acceptable form birth control participation study . Have voluntarily sign write Informed Consent accordance institutional policy content fully explain . Exclusion Criteria Pregnant lactating . Positive HIV hepatitis C baseline selfreport . Potential participant coagulopathies , include thrombocytopenia platelet count &lt; 75,000 , INR &gt; 1.5 partial thromboplastin time &gt; 50 sec Major cardiac illness MUGA ECHO &lt; 50 % EF . Preexisting medical illness medication might interfere study determine Principal Investigator ( PI ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ductal carcinoma situ ( DCIS )</keyword>
</DOC>